Most telling though, the results that show that the overall obesity rate in the U.S. has not changed significantly in a ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The low-cost carrier is having a nightmarish 2024, with its shares down 86% even before Thursday's news. The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Doctors and law enforcement are raising concerns about the growing trend of people selling weight loss drugs like Ozempic and ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...